IPM valued at Rs 89,244 crores
IMS Health, provider of healthcare consulting, technology, and informatics, has posted the market reflection report for February 2015.
The Indian pharmaceutical market (IPM) was valued at Rs 89,244 crores and the retail sector was valued at Rs 75,551 crores, both with a growth of 20 per cent in February 2015 over the same month last year. IPM posted CAGR growth of 11 per cent during the period 2012-15. Multiple factors like prevalence of swine flu-H1N1, high growth in anti-infectives, respiratory and pain market with expansion of big brands, has resulted in overall robust IPM growth of 20 per cent for the month. Indian companies continue to drive growth in the market with a growth of 22 per cent in February 2015. Cardiac and gastro Intestinal, with respective market share of 12 per cent and 10 per cent, constitutes the second and third largest therapies.
The top 10 companies constituted 40 per cent market share of IPM on MAT and month basis. Similarly, the top 150 companies constituted 97 per cent market share of IPM on MAT and month basis. For the top companies, growth was driven by top 300 brands which grew by 11 per cent for top one to 10 companies.
In total sales audit (TSA), Macleods, Mankind and Cipla registered remarkable growth both on MAT and month basis, while in secondary sales audit (SSA), Macleods registered the highest growth both on MAT and month basis followed by Mankind.
Intas continued to register the highest growth of 39 per cent on month basis and 20 per cent on MAT basis among the top 11-20 companies in TSA and in SSA, additional to Intas, few companies have registered significant growth on month basis such as Aristo Pharma, Alembic and Dr Reddys Labs; while Glenmark Pharma posted significant growth on MAT basis.
IPCA continued to register significant growth of 39 per cent during the month followed by Wockhardt and Cadila Pharma in TSA and in SSA, apart from IPCA, Cadila registered significant growth of 35 per cent during the month followed by Wockhardt at 25 per cent.
In the month of February 2015 (in comparison to January 2015), among the top 25 companies, in TSA, Macleods Pharma has gained three ranks and moved to the seventh position. Mankind, Aristo Pharma and Wockhardt have gained two ranks each and moved to fourth, 17th and 22nd position, respectively. Alkem, Alembic and FDC have gained one rank each and moved to 8th, 20th and 25th position, respectively. As per February 2015 MAT (in comparison to January 15) among the top 25 companies, Abbott has maintained its top position with market share of 6.37 per cent and Alkem has gained one rank and moved to the seventh position.
Under SSA, in the month of February 2015 (in comparison to January 2015), among the TOP 25 companies, Abbott has maintained its top position with market share of 6.31 per cent. Aristo Pharma has gained four ranks and occupied 14th position. Macleods Pharma has gained three ranks and occupied the fifth position. Wockhardt has gained two ranks and occupied 22nd position.
Intas and FDC have gained one rank each and occupied 11th and 25th position, respectively. As per February 2015 MAT (in comparison to January 2015 MAT), among the TOP 25 companies, Abbott has maintained its top position with market share of 6.53 per cent. Macleods Pharma has gained one rank and occupied the eighth position.
NLEM impacted drugs constituted 13 per cent of IPM in value terms with a growth of 11.5 per cent in February ‘15 over same period last year (SPLY). The share of the non-NLEM drugs was 87 per cent of IPM in value terms and 78 per cent in volume terms for the month of February 2015. The volume of NLEM drugs witnessed growth of eight per cent in February 2015 over the same period last year.
Indian/ MNC trends
Indian companies continue to capture the larger share of IPM at 74 per cent during the month with a significant growth of 22 per cent over February 2014. With three MNCs represented in the top 10 companies, the share of MNCs constituted 26 per cent of IPM.
Acute/ Chronic trends
Acute therapies continue to dominate the market accounting for 70 per cent of the market during the month. Chronic therapies registered growth of 18 per cent, while acute therapies attained significant growth of 20 per cent over February 2014. Cough preparation was the highest selling therapeutic subgroup in value terms with significant growth of 35 per cent on month basis.
Alburel (Reliance Life Sciences) registered outstanding growth of 118 per cent during the month. Being a new launch, Biovac V (Wockhardt) has registered astounding growth and attained its position in top 40 brands. Magnex (Pfizer), Prevenar-13 (Pfizer), Panderm+ (Macleods), Thyronorm (Abbott) and Electral (FDC) posted impressive growth greater than 50 per cent in February 2015 over the same month last year.
Star brands of the month
Under TSA, the following top 25 products as per February 2015 (in comparison to January 2015) are: Mixtard (Abbott) as the number one brand, Alburel (Reliance Life Sciences) has gained 29 ranks to occupy the 25th position. Monocef (Aristo Pharmaceuticals) has gained 12 ranks to occupy the ninth position. Dexorange (Franco-Indian) and Moxikind CV (Mankind) has gained nine ranks to occupy 17th and 24th position, respectively. Panderm+ (Macleods) and Clavam (Alkem) has gained six ranks to occupy 6th and 7th position, respectively. Thyronorm (Abbott), Betadine (Win Medicare), Electral (FDC) and Liv-52 (Himalaya) have gained two ranks each to occupy 5th ,15th, 20th and 21st position, respectively. Augmentin (GSK) and Volini (Ranbaxy) have gained one rank each to occupy 2nd and 13th position, respectively.
Among the Top 25 products as per February 2015 MAT (in comparison to January 2015 MAT), Mixtard (Abbott) is the number one brand. Panderm + (Macleods) has gained three ranks to occupy the 21st position. Prevenar-13 (Pfizer) has gained two ranks to occupy 9th position. Volini (Ranbaxy), Dexorange (Franco-Indian), Thyronorm (Abbott), Novomix (Abbott), Janumet (MSD) and Shelcal (Torrent Pharma) have gained one rank each to occupy 6th, 7th, 8th,14th, 17th and 24th position, respectively.
Vaccines recorded significant value growth of 42 per cent as of MAT February 2015. The anti-infectives constitute the largest market share of 15 per cent, with significant growth both on month and MAT basis.
Oral electrolytes, budesonide, amikacin and cough Prep. Ethicals registered significant growth greater than 30 per cent over the same period last year.
EP News Bureau – Mumbai